Results 111 to 120 of about 9,615 (165)

Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
In treatment‐naïve CLL, a shortened obinutuzumab infusion was as safe as standard infusion, did not increase infusion‐related reactions, and significantly reduced chair time, improving outpatient unit efficiency. ABSTRACT Background Obinutuzumab‐based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion ...
Dominika Écsiová   +6 more
wiley   +1 more source

Age, Comorbidity Burden and Treatment Outcomes in Mature B‐Cell Lymphoproliferative Disorders: A Real‐World Study

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Introduction Treatment decisions in older patients with mature B‐cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain.
Kevin Nasrinfar   +6 more
wiley   +1 more source

Zanubrutinib Combined With Venetoclax for the Treatment of Central Nervous System‐Involved Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case Report

open access: yesCancer Reports, Volume 9, Issue 11, November 2026.
ABSTRACT Background Clinically significant CNS involvement by CLL/SLL is uncommon, diagnostically challenging, and has no established standard treatment. Case A 61‐year‐old man with previously untreated CLL/SLL was admitted in April 2023 to Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, with rapidly
Wei Xie   +4 more
wiley   +1 more source

Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy

open access: yes, 2019
There is increasing evidence that rates of atrial arrhythmias (AA), specifically atrial fibrillation and flutter are elevated in patients treated with the tyrosine kinase inhibitor, ibrutinib; however, the exact risk of ibrutinib-associated AA is not ...
Viganego, Federico   +13 more
core   +1 more source

Salicylic Acid as a Food‐Derived Bioactive Constituent of Tiaoqi Daozhi Decoction: A Potential Functional Food Ingredient to Restoring Gut Barrier Function in Constipation‐Predominant IBS

open access: yesFood Science &Nutrition, Volume 14, Issue 11, November 2026.
Tiaoqi Daozhi Decoction (TQDZD) is a classic formulation composed of eight medicine‐food homologous botanicals. UPLC‐MS/MS profiling identified 1962 non‐redundant compounds in its aqueous extract, predominantly phenolic acids and flavonoids, of which 107 metabolites were systemically bioavailable.
Min Duan   +4 more
wiley   +1 more source

Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC

open access: yesHemaSphere, Volume 10, Issue 11, November 2026.
Abstract The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax‐based ...
Candida Vitale   +106 more
wiley   +1 more source

Supplemental figures from Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells

open access: yes, 2017
Figure 1. Structures of acalabrutinib and ibrutinib. A. Chemical structure of acalabrutinib. B. Chemical structure of ibrutinib.
Mary Ayres (356964)   +6 more
core   +1 more source

Ibrutinib-associated osteonecrosis of the jaw

open access: yes
Ibrutinib is an FDA-approved first-generation oral Bruton tyrosine kinase (BTK) inhibitor that has been used in the treatment of patients with chronic lymphocytic leukemia (CLL).
Joseph M. Huryn   +5 more
core   +1 more source

Decision‐Making on First‐Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi‐Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy

open access: yesHematological Oncology, Volume 44, Issue 6, November 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries. The introduction of targeted therapies has expanded first‐line treatment options, which differ across multiple relevant dimensions, making therapeutic decisions increasingly challenging.
Paolo Sportoletti   +10 more
wiley   +1 more source

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy